A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Latest Information Update: 14 May 2025
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CANOPY
Most Recent Events
- 26 Mar 2025 Planned number of patients changed from 50 to 47.
- 02 Jul 2024 Planned End Date changed from 12 Oct 2024 to 12 Apr 2027.
- 02 Jul 2024 Planned primary completion date changed from 12 May 2024 to 12 Apr 2026.